Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Holding ASRT?
Track your performance easily
ASRT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $1.80
Previous Close$0.94
Volume700.07K
Average Volume (3M)596.81K
Market Cap
$89.83M
Enterprise Value$40.09M
Total Cash (Recent Filing)$88.58M
Total Debt (Recent Filing)$38.84M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Mar 05, 2025EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding95,477,800
10 Day Avg. Volume1,416,738
30 Day Avg. Volume596,814
Standard Deviation0.25
R-Squared0.00145
Alpha0.00226
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)0.74
Price to Cash Flow (P/CF)-664.90
P/FCF Ratio31.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.32
Enterprise Value/Ebitda-2.60
Forecast
1Y Price Target
$2.72Price Target Upside189.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Assertio Therapeutics News
PremiumCompany Announcements
Assertio Therapeutics Reports Strong Q3 and Board Changes
PremiumCompany Announcements
Assertio Therapeutics’ Q3 2024 Earnings Overview
Bulls Say, Bears Say
Bulls Say
Growth StrategyAssertio's strategy has been to acquire commercial products requiring minimal investment to add to its portfolio, leading to inorganic growth and increasing cash flow.
Market ValuationShares currently trade at an 87% discount to its peers on a 2025 EV/revenue basis, making ASRT shares an attractive bet when trading at only 0.5x 2025 revenues.
Product DifferentiationRolvedon is competing in a biosimilar Neulasta market but is differentiated as it can potentially be injected the same day as chemo, which could be a meaningful opportunity.
Bears Say
Generic CompetitionThe launch by Zydus of a generic was an unfortunate occurrence for the Company’s self-described unicorn product.
Legal DisputeAssertio is engaged in an ongoing dispute with Buxton Hemsley Group, Inc., and management claims Buxton’s statements are 'baseless allegations'.
Revenue DeclineIndocin revenues continuing to diminish, and mixed performances from the other portfolio products, acquisitions will be key to sustaining long-term growth.
---
Ownership Overview
2.15% Insiders
8.12% Mutual Funds
11.59% Other Institutional Investors
72.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $0.73 and its highest was $1.80 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Currently, no data Available
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Mar 05, 2025 which is in 102 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Nov 11, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.046 by $0.016.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -$0.05.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 95,477,800 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.046. Following the earnings report the stock price went down -7.609%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Among the largest hedge funds holding Assertio Therapeutics Inc’s share is Royce & Associates LLC. It holds Assertio Therapeutics Inc’s shares valued at 89K.
---
Assertio Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.72 (189.12% Upside)
$2.72 (189.12% Upside)
Blogger Sentiment
Bullish
ASRT Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $70.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.19%
12-Months-Change
Fundamentals
Return on Equity
-42.36%
Trailing 12-Months
Asset Growth
-27.37%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
---
ASRT Earnings Call
Q3 2024
0:00 / 0:00
---
ASRT Stock 12 Month Forecast
Average Price Target
$2.72
▲(189.12% Upside)
Technical Analysis
Aldeyra Therapeutics
―
TuHURA Biosciences
―
Relmada Therapeutics
―
Aileron Therapeutics
―
Best Analysts Covering ASRT
1 Year
1 Year Success Rate
8/31 ratings generated profit
1 Year Average Return
-26.16%
reiterated a buy rating 12 days ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 25.81% of your transactions generating a profit, with an average return of -26.16% per trade.
---